ATL Technology Acquires Gyrus Medical LTD. Manufacturing Operations

ATL Technology (ATL), a fast-growing provider of outsourced design, development and manufacturing services to the medical device market, today announced it has acquired manufacturing operations of Gyrus Medical Limited (Gyrus/GML) from Olympus Winter & Ibe GmbH (Olympus Surgical Technologies Europe).

Gyrus Medical is located in Cardiff, Wales, United Kingdom, is also a device outsourcer, and will increase both ATL’s global footprint and capabilities. In discussing this transaction, Joe Glover, CEO of ATL said, “This is a very strategic event for ATL. We look forward to incorporating Gyrus’ capabilities into ATL’s existing offerings and to expand our global footprint deeper onto the European continent.”

“We are also enthusiastic about welcoming the Gyrus team to ATL. Their significant engineering capabilities will enhance ATL’s existing resources, allowing ATL to continue its impressive growth rates”, said Glover.
Gyrus Executive Managing Director Simon Edwards said, “Over the past 30 years, Gyrus, much like ATL, has worked with medical device original equipment manufacturer (OEM) customers to develop and manufacture innovative solutions to improve patient care. We are looking forward to this strategic combination to continue and enhance this work for our OEM customers.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version